JP6462681B2 - イオン交換クロマトグラフィーのインプットの最適化の解明 - Google Patents

イオン交換クロマトグラフィーのインプットの最適化の解明 Download PDF

Info

Publication number
JP6462681B2
JP6462681B2 JP2016525805A JP2016525805A JP6462681B2 JP 6462681 B2 JP6462681 B2 JP 6462681B2 JP 2016525805 A JP2016525805 A JP 2016525805A JP 2016525805 A JP2016525805 A JP 2016525805A JP 6462681 B2 JP6462681 B2 JP 6462681B2
Authority
JP
Japan
Prior art keywords
polypeptide
antibody
buffer
contaminants
gradient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016525805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529489A5 (enExample
JP2016529489A (ja
Inventor
ダニエル マクドナルド，
ダニエル マクドナルド，
トーマス パタポフ，
トーマス パタポフ，
ヤーチュン ワン，
ヤーチュン ワン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2016529489A publication Critical patent/JP2016529489A/ja
Publication of JP2016529489A5 publication Critical patent/JP2016529489A5/ja
Application granted granted Critical
Publication of JP6462681B2 publication Critical patent/JP6462681B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8658—Optimising operation parameters
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/28—Control of physical parameters of the fluid carrier
    • G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Confectionery (AREA)
JP2016525805A 2013-07-12 2014-07-11 イオン交換クロマトグラフィーのインプットの最適化の解明 Active JP6462681B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845890P 2013-07-12 2013-07-12
US61/845,890 2013-07-12
PCT/US2014/046338 WO2015006686A1 (en) 2013-07-12 2014-07-11 Elucidation of ion exchange chromatography input optimization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018242206A Division JP2019090818A (ja) 2013-07-12 2018-12-26 イオン交換クロマトグラフィーのインプットの最適化の解明

Publications (3)

Publication Number Publication Date
JP2016529489A JP2016529489A (ja) 2016-09-23
JP2016529489A5 JP2016529489A5 (enExample) 2017-08-31
JP6462681B2 true JP6462681B2 (ja) 2019-01-30

Family

ID=51257626

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016525805A Active JP6462681B2 (ja) 2013-07-12 2014-07-11 イオン交換クロマトグラフィーのインプットの最適化の解明
JP2018242206A Pending JP2019090818A (ja) 2013-07-12 2018-12-26 イオン交換クロマトグラフィーのインプットの最適化の解明

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018242206A Pending JP2019090818A (ja) 2013-07-12 2018-12-26 イオン交換クロマトグラフィーのインプットの最適化の解明

Country Status (18)

Country Link
US (2) US10274466B2 (enExample)
EP (2) EP3019516B1 (enExample)
JP (2) JP6462681B2 (enExample)
KR (1) KR102251127B1 (enExample)
CN (1) CN105377873B (enExample)
AU (1) AU2014287044B2 (enExample)
BR (1) BR112016000231A8 (enExample)
CA (1) CA2918052A1 (enExample)
ES (1) ES2705700T3 (enExample)
HR (1) HRP20190071T1 (enExample)
IL (1) IL243305B (enExample)
MX (1) MX368107B (enExample)
PL (1) PL3019516T3 (enExample)
RU (1) RU2016104542A (enExample)
SG (1) SG11201600221YA (enExample)
SI (1) SI3019516T1 (enExample)
TR (1) TR201818966T4 (enExample)
WO (1) WO2015006686A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102251127B1 (ko) 2013-07-12 2021-05-11 제넨테크, 인크. 이온 교환 크로마토그래피 입력 최적화의 설명
JP6656710B2 (ja) * 2014-11-12 2020-03-04 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ 液体クロマトグラフィープロトコルにおける実験パラメータの影響を決定するための方法及びシステム
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions
SG11202009629YA (en) * 2018-04-02 2020-10-29 Amgen Inc Erenumab compositions and uses thereof
WO2020010304A2 (en) * 2018-07-05 2020-01-09 Ovation Diagnostics Llc BCl-2 Antibodies and Immunoassay for Diagnosis of Cancer
KR20200080748A (ko) * 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
WO2024261724A1 (en) * 2023-06-23 2024-12-26 Lupin Limited Ion-exchange chromatography for separation and analysis of charge variants

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666855A (en) * 1985-07-31 1987-05-19 Massachusetts Institute Of Technology Rapid method for determining the isoelectric point for amphoteric molecules
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2037273T3 (es) 1987-04-11 1993-06-16 Ciba-Geigy Ag Proceso de focalizacion isoelectrica y medios para llevar a cabo dicho proceso.
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
SE9803838D0 (sv) * 1998-11-09 1998-11-09 Knut Irgum A chromatography method and a column material useful in said method
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
ES2376454T3 (es) 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan Librer�?as de expresión en fago de fragmentos vh humanos.
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
PT1543038T (pt) 2002-09-11 2017-07-07 Genentech Inc Purificação de proteína
EP1628729A2 (en) 2003-05-16 2006-03-01 Cryobiophysica, Inc. External gradient chromatofocusing
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
US7906630B2 (en) 2004-04-27 2011-03-15 PerkinElmer Heath Sciences, Inc. Method for identifying peptides in a biological sample
JP5008564B2 (ja) 2004-05-20 2012-08-22 ウオーターズ・テクノロジーズ・コーポレイシヨン 混合物中のタンパク質を同定する方法および装置
EP1781778A4 (en) 2004-06-16 2007-09-12 Ciphergen Biosystems Inc MULTICHEMIEFRAKTIONIERUNG
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JP2006087394A (ja) * 2004-09-27 2006-04-06 Wako Pure Chem Ind Ltd 核酸抽出方法および核酸抽出キット
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
JP2010089001A (ja) 2008-10-07 2010-04-22 Japan Organo Co Ltd クロマト分離方法
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
JP5540095B2 (ja) 2009-07-24 2014-07-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗体製造の最適化
BR112012004697B8 (pt) * 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
EP2590736A4 (en) 2010-07-09 2015-04-01 Ge Healthcare Bio Sciences Ab CHROMATOGRAPHY METHOD AND MEDIA USED THEREFOR
TW201235799A (en) 2011-01-24 2012-09-01 Sharp Kk Exposure apparatus, liquid crystal display device and method for manufacturing same
CA2831429A1 (en) 2011-03-31 2012-10-04 Apotex Technologies Inc. Prodrugs of d-gamma-glutamyl-d-tryptophan and d-gamma- glutamyl-l-tryptophan
JP2015537212A (ja) 2012-11-15 2015-12-24 ジェネンテック， インコーポレイテッド イオン強度媒介のｐｈ勾配イオン交換クロマトグラフィー
KR102251127B1 (ko) 2013-07-12 2021-05-11 제넨테크, 인크. 이온 교환 크로마토그래피 입력 최적화의 설명

Also Published As

Publication number Publication date
JP2019090818A (ja) 2019-06-13
SG11201600221YA (en) 2016-02-26
WO2015006686A8 (en) 2018-10-04
IL243305A0 (en) 2016-03-31
WO2015006686A1 (en) 2015-01-15
US10921297B2 (en) 2021-02-16
EP3019516B1 (en) 2018-11-14
TR201818966T4 (tr) 2019-01-21
MX2016000181A (es) 2016-03-09
IL243305B (en) 2019-09-26
BR112016000231A8 (pt) 2019-12-31
CN105377873A (zh) 2016-03-02
KR20160030251A (ko) 2016-03-16
EP3536699A1 (en) 2019-09-11
RU2016104542A (ru) 2017-08-17
AU2014287044B2 (en) 2020-02-06
CN105377873B (zh) 2021-03-30
EP3019516A1 (en) 2016-05-18
HK1222183A1 (zh) 2017-06-23
SI3019516T1 (sl) 2019-02-28
JP2016529489A (ja) 2016-09-23
ES2705700T3 (es) 2019-03-26
PL3019516T3 (pl) 2019-04-30
US20190310234A1 (en) 2019-10-10
US20160161455A1 (en) 2016-06-09
HRP20190071T1 (hr) 2019-02-22
CA2918052A1 (en) 2015-01-15
KR102251127B1 (ko) 2021-05-11
AU2014287044A1 (en) 2016-02-11
MX368107B (es) 2019-09-18
US10274466B2 (en) 2019-04-30

Similar Documents

Publication Publication Date Title
US10712322B2 (en) Ionic strength-mediated pH gradient ion exchange chromatography
JP6356607B2 (ja) オーバーロード／溶出クロマトグラフィー
JP6602765B2 (ja) クロマトグラフィー再使用のための方法
AU2022291517B2 (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
US10921297B2 (en) Elucidation of ion exchange chromatography input optimization
AU2011258254B2 (en) Methods of purifying polypeptides
HK1222183B (en) Elucidation of ion exchange chromatography input optimization
HK40007967A (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170721

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181227

R150 Certificate of patent or registration of utility model

Ref document number: 6462681

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250